Marc Joan Van De Vijver
#163,551
Most Influential Person Now
Marc Joan Van De Vijver's AcademicInfluence.com Rankings
Marc Joan Van De Vijverbiology Degrees
Biology
#13104
World Rank
#16630
Historical Rank
Genetics
#1450
World Rank
#1552
Historical Rank
Molecular Biology
#2175
World Rank
#2209
Historical Rank
Download Badge
Biology
Marc Joan Van De Vijver's Degrees
- PhD Molecular Biology University of Amsterdam
- Masters Biomedical Sciences University of Amsterdam
- Bachelors Biomedical Sciences University of Amsterdam
Why Is Marc Joan Van De Vijver Influential?
(Suggest an Edit or Addition)Marc Joan Van De Vijver's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Long noncoding RNA HOTAIR reprograms chromatin state to promote cancer metastasis (2010) (4719)
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. (2006) (3857)
- A gene-expression signature as a predictor of survival in breast cancer. (2002) (3325)
- Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. (2006) (1930)
- International network of cancer genome projects (2010) (1839)
- A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. (2007) (1584)
- Landscape of somatic mutations in 560 breast cancer whole genome sequences (2016) (1574)
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. (2007) (1419)
- Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. (2001) (1162)
- Assessment of a HER2 scoring system for gastric cancer: results from a validation study (2008) (1091)
- Extensive and coordinated transcription of noncoding RNAs within cell cycle promoters (2011) (1066)
- An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. (2008) (993)
- Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. (2005) (989)
- Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. (1988) (872)
- The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. (2002) (842)
- Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. (1998) (700)
- HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures (2017) (644)
- Systematic Analysis of Breast Cancer Morphology Uncovers Stromal Features Associated with Survival (2011) (632)
- Gene Expression Programs in Response to Hypoxia: Cell Type Specificity and Prognostic Significance in Human Cancers (2006) (628)
- Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas (2007) (598)
- Ductal carcinoma in situ: a proposal for a new classification. (1994) (560)
- Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. (2001) (478)
- An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer (2008) (464)
- Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothe (2017) (408)
- Lung metastasis genes couple breast tumor size and metastatic spread (2007) (395)
- Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets (2009) (385)
- Patterns of somatic structural variation in human cancer genomes (2020) (377)
- Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial. (2012) (369)
- Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer (2014) (358)
- E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. (1997) (349)
- Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene (1987) (348)
- MicroRNA sequence and expression analysis in breast tumors by deep sequencing. (2011) (348)
- Diagnosis of breast cancer: contribution of US as an adjunct to mammography. (1999) (308)
- Simultaneous loss of E‐cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ (1997) (304)
- Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome (2003) (302)
- Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. (2011) (300)
- Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes (2014) (289)
- Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). (2007) (277)
- A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. (2005) (263)
- Local recurrence after breast-conserving therapy for invasive breast cancer: high incidence in young patients and association with poor survival. (1998) (260)
- Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. (1999) (252)
- Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. (2012) (252)
- The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. (2000) (239)
- Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. (1992) (213)
- Predicting a local recurrence after breast-conserving therapy by gene expression profiling (2006) (209)
- Receptor conversion in distant breast cancer metastases (2010) (209)
- Somatic mutations reveal asymmetric cellular dynamics in the early human embryo (2017) (204)
- Determination of Stromal Signatures in Breast Carcinoma (2005) (201)
- Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer (2009) (200)
- The topography of mutational processes in breast cancer genomes (2016) (198)
- Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
- Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. (2005) (189)
- Expression profiling predicts outcome in breast cancer (2002) (183)
- An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients (2010) (182)
- p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. (1998) (181)
- Classification of ductal carcinoma in situ by gene expression profiling (2006) (181)
- The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. (2010) (157)
- The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans (2007) (151)
- Emerging technologies for assessing HER2 amplification. (2009) (144)
- Retrospective analysis of metastatic behaviour of breast cancer subtypes (2015) (136)
- Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up (2004) (133)
- Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. (1996) (128)
- A conditional mouse model for malignant mesothelioma. (2008) (123)
- Expression of the breast cancer resistance protein in breast cancer. (2002) (116)
- Immunohistochemical categorisation of ductal carcinoma in situ of the breast (2007) (115)
- Prevalence of serrated polyps and association with synchronous advanced neoplasia in screening colonoscopy (2013) (114)
- Association of C‐MYC amplification with progression from the in situ to the invasive stage in C‐MYC‐amplified breast carcinomas (2003) (108)
- Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer (2016) (107)
- Immunohistochemical detection of the neu protein in tissue sections of human breast tumors with amplified neu DNA. (1988) (106)
- Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer (2009) (104)
- ONCOPOOL - a European database for 16,944 cases of breast cancer. (2010) (103)
- Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ (2001) (103)
- Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations. (1994) (102)
- Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results. (2008) (100)
- Continuing risk of ipsilateral breast relapse after breast-conserving therapy at long-term follow-up. (2008) (98)
- Integration of a Radiosensitivity Molecular Signature Into the Assessment of Local Recurrence Risk in Breast Cancer. (2015) (94)
- Local Recurrence after Breast-Conserving Therapy in Relation to Gene Expression Patterns in a Large Series of Patients (2009) (93)
- The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer. (1999) (93)
- Long-term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer. (2005) (91)
- First-in-Human Ultrasound Molecular Imaging With a VEGFR2-Specific Ultrasound Molecular Contrast Agent (BR55) in Prostate Cancer: A Safety and Feasibility Pilot Study (2017) (91)
- Pooling breast cancer datasets has a synergetic effect on classification performance and improves signature stability (2008) (90)
- Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902 (2009) (90)
- Pseudomyxoma peritonei: a review of 62 cases. (2003) (90)
- Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients (2004) (89)
- Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis? (2000) (88)
- High local recurrence risk after breast-conserving therapy in node-negative premenopausal breast cancer patients is greatly reduced by one course of perioperative chemotherapy: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study. (2000) (87)
- Processed pseudogenes acquired somatically during cancer development (2014) (87)
- Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration (2016) (86)
- Genetic alterations during the progression of squamous cell carcinomas of the uterine cervix (1999) (80)
- Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. (2011) (80)
- Determining MDR1/P‐glycoprotein expression in breast cancer (2001) (79)
- Histological determinants for different types of local recurrence after breast-conserving therapy of invasive breast cancer. Dutch Study Group on local Recurrence after Breast Conservation (BORST) (1999) (78)
- Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. (2009) (78)
- Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome? (2003) (76)
- Integration of DNA Copy Number Alterations and Prognostic Gene Expression Signatures in Breast Cancer Patients (2010) (74)
- Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: a case-control study of histological factors and alterations in oncogene expression. (1998) (74)
- Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. (2004) (73)
- Loss of heterozygosity for defined regions on chromosomes 3, 11 and 17 in carcinomas of the uterine cervix. (1998) (73)
- A novel gene expression signature for bone metastasis in breast carcinomas (2016) (72)
- Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival (2018) (71)
- Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. (2006) (71)
- Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study (2007) (70)
- The circular RNome of primary breast cancer (2019) (70)
- BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations (2010) (69)
- Comparison of surveillance and retroperitoneal lymph node dissection in Stage I nonseminomatous germ cell tumors. (2002) (69)
- Unusual origins of pseudomyxoma peritonei (2000) (69)
- Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy (2006) (68)
- Long-term impact of the 70-gene signature on breast cancer outcome (2014) (68)
- A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers (2017) (67)
- Cyclin D1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast (1999) (66)
- Gene Expression Programs of Human Smooth Muscle Cells: Tissue-Specific Differentiation and Prognostic Significance in Breast Cancers (2007) (66)
- Functional characterization of the 19q12 amplicon in grade III breast cancers (2012) (65)
- Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets (2014) (65)
- Reliability of core needle biopsy for determining ER and HER2 status in breast cancer. (2013) (65)
- Search for a Gene Expression Signature of Breast Cancer Local Recurrence in Young Women (2012) (65)
- Establishment of patient-derived xenograft models and cell lines for malignancies of the upper gastrointestinal tract (2015) (64)
- Gene Expression Profiles of Primary Breast Carcinomas from Patients at High Risk for Local Recurrence after Breast-Conserving Therapy (2006) (63)
- The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment. (2010) (63)
- Adjuvant radiotherapy following radical hysterectomy for patients with early-stage cervical carcinoma (1984-1996). (1999) (62)
- Predictive factors for local recurrence in breast cancer. (2012) (62)
- Different mechanisms of chromosome 16 loss of heterozygosity in well‐ versus poorly differentiated ductal breast cancer (2004) (60)
- Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer (2020) (60)
- The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992). (2003) (59)
- Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. (2002) (58)
- First results of the preoperative accelerated partial breast irradiation (PAPBI) trial. (2015) (57)
- Revealing targeted therapy for human cancer by gene module maps. (2008) (57)
- Recent developments in the molecular genetic understanding of breast cancer. (1994) (56)
- Radiation-associated breast tumors display a distinct gene expression profile. (2010) (55)
- Downgrading of Breast Masses Suspicious for Cancer by Using Optoacoustic Breast Imaging. (2018) (54)
- Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach (2012) (54)
- Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group (2020) (54)
- The molecular biology of breast cancer. (1991) (53)
- Assessment of Problems in Diagnostic and Research Immunohistochemistry Associated With Epitope Instability in Stored Paraffin Sections (2000) (53)
- Improving patient care through molecular diagnostics. (2004) (52)
- A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923. (2000) (52)
- Prognosis and prognostic factors of patients with mesothelioma: a population-based study (2012) (52)
- Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis. (2017) (51)
- Robust prognostic value of a knowledge-based proliferation signature across large patient microarray studies spanning different cancer types (2008) (51)
- Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma (2019) (51)
- Integration of Clinical and Gene Expression Data Has a Synergetic Effect on Predicting Breast Cancer Outcome (2012) (50)
- Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer. (2004) (49)
- Predicting Early Failure after Adjuvant Chemotherapy in High-Risk Breast Cancer Patients with Extensive Lymph Node Involvement (2004) (49)
- Molecularly Defined Adult Granulosa Cell Tumor of the Ovary: The Clinical Phenotype. (2016) (47)
- A simple system for grading the response of breast cancer to neoadjuvant chemotherapy. (2010) (47)
- Very low local recurrence rates after breast-conserving therapy: analysis of 8485 patients treated over a 28-year period (2016) (47)
- Discordance in ERα, PR and HER2 receptor status across different distant breast cancer metastases within the same patient. (2013) (47)
- Impact of established prognostic factors and molecular subtype in very young breast cancer patients: pooled analysis of four EORTC randomized controlled trials (2011) (46)
- External Validation of Adjuvant! Online Breast Cancer Prognosis Tool. Prioritising Recommendations for Improvement (2011) (45)
- Using microarray analysis as a prognostic and predictive tool in oncology: focus on breast cancer and normal tissue toxicity. (2008) (45)
- Surveillance can be the standard of care for stage I nonseminomatous testicular tumors and even high risk patients. (2001) (45)
- The diagnosis and management of pre-invasive breast disease: Pathological diagnosis – problems with existing classifications (2003) (44)
- HLA-G Expression Is an Independent Predictor for Improved Survival in High Grade Ovarian Carcinomas (2014) (43)
- Expression of endoplasmic reticulum stress proteins is a candidate marker of brain metastasis in both ErbB-2+ and ErbB-2- primary breast tumors. (2011) (42)
- Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity. (1998) (42)
- Locoregional recurrence after breast-conserving therapy remains an independent prognostic factor even after an event free interval of 10 years in early stage breast cancer. (2012) (41)
- Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. (2012) (41)
- Sex differences in oncogenic mutational processes (2019) (41)
- Prognostic value of DNA cytometry in 281 premenopausal patients with lymph node negative breast carcinoma randomized in a control trial (2000) (40)
- Human papillomavirus in malignant cervical lesions in Surinam, a high-risk country, compared to the Netherlands, a low-risk country. (1999) (40)
- Genomic evolution from primary breast carcinoma to distant metastasis: Few copy number changes of breast cancer related genes. (2014) (39)
- Role of MRI in detecting involvement of the uterine internal os in uterine cervical cancer: systematic review of diagnostic test accuracy. (2013) (39)
- Partially methylated domains are hypervariable in breast cancer and fuel widespread CpG island hypermethylation (2018) (37)
- Isolated late local recurrences with high mitotic count and early local recurrences following breast-conserving therapy are associated with increased risk on distant metastasis. (2001) (37)
- Unsupervised class discovery in pancreatic ductal adenocarcinoma reveals cell-intrinsic mesenchymal features and high concordance between existing classification systems (2020) (36)
- The Snf1-related kinase, Hunk, is essential for mammary tumor metastasis (2009) (34)
- Mutations in exons 5–8 of the p53 gene, independent of their type and location, are associated with increased apoptosis and mitosis in invasive breast carcinoma (1999) (33)
- Combining biological gene expression signatures in predicting outcome in breast cancer: An alternative to supervised classification. (2008) (33)
- Risk of benign meningioma after childhood cancer in the DCOG-LATER cohort: contributions of radiation dose, exposed cranial volume, and age (2018) (33)
- HER2 gene amplification in patients with breast cancer with equivocal IHC results (2011) (32)
- ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy (2018) (31)
- HER-2 amplification is highly homogenous in gastric cancer. (2010) (30)
- Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice. (2011) (30)
- Constructive Technology Assessment (CTA) as a tool in Coverage with Evidence Development: The case of the 70-gene prognosis signature for breast cancer diagnostics (2009) (29)
- Dilemmas for the pathologist in the oncologic assessment of pancreatoduodenectomy specimens (2018) (29)
- Diagnosing occult tumour cells and their predictive value in sentinel nodes of histologically negative patients with colorectal cancer. (2010) (29)
- Epithelial-to-mesenchymal transition status of primary breast carcinomas and its correlation with metastatic behavior (2019) (29)
- Efficacy of adjuvant chemotherapy according to hormone receptor status in young patients with breast cancer: a pooled analysis (2007) (28)
- Amplification and over-expression of the neu oncogene in human breast carcinomas. (1988) (28)
- A specific gene expression signature for visceral organ metastasis in breast cancer (2019) (27)
- Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2). (2001) (27)
- High‐grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF‐1 (2020) (26)
- Computer tomography colonography participation and yield in patients under surveillance for 6-9 mm polyps in a population-based screening trial (2015) (25)
- Mutation of the human neu protein facilitates down-modulation by monoclonal antibodies. (1990) (24)
- Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer (2019) (23)
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
- Colorectal Adenomas and Cancers After Childhood Cancer Treatment: A DCOG-LATER Record Linkage Study (2018) (21)
- Colorectal Adenomas and Cancers After Childhood Cancer Treatment: A DCOG-LATER Record Linkage Study (2018) (21)
- Gene expression signatures to predict the development of metastasis in breast cancer. (2006) (21)
- Biological variables and prognosis of DCIS. (2005) (19)
- Postmastectomy radiotherapy: will the selective use of postmastectomy radiotherapy study end the debate? (2009) (19)
- PTEN and NEDD4 in Human Breast Carcinoma (2015) (19)
- Crossing borders: A systematic review with quantitative analysis of genetic mutations of carcinomas of the biliary tract. (2019) (19)
- Comparison of the Genetic Alterations in Two Epithelial Collision Tumors of the Uterine Cervix. A Report of Two Cases (2000) (18)
- Pathological validation and prognostic potential of quantitative MRI in the characterization of pancreas cancer: preliminary experience (2020) (17)
- Confocal Laser Endomicroscopy as a Guidance Tool for Pleural Biopsies in Malignant Pleural Mesothelioma. (2019) (17)
- Emerging Technologies for HER2 Testing (2002) (15)
- Gene-expression profiling and the future of adjuvant therapy. (2005) (15)
- DNA ploidy of primary breast cancer and local recurrence after breast-conserving therapy. (1991) (15)
- Molecular tests as prognostic factors in breast cancer. (2014) (14)
- Multicentre study on the consistency of PD-L1 immunohistochemistry as predictive test for immunotherapy in non-small cell lung cancer (2019) (14)
- Optoacoustic imaging of the breast: correlation with histopathology and histopathologic biomarkers (2019) (13)
- Lost in translation: confusion on resection and dissection planes hampers the interpretation of pathology reports for perihilar cholangiocarcinoma (2019) (12)
- Are triple-negative tumours and basal-like breast cancer synonymous? Authors' response (2007) (12)
- Response to preoperative radiotherapy in relation to gene expression patterns in breast cancer patients. (2017) (11)
- Differentiation-dependent expression of provirus-activated int-1 oncogene in clonal cell lines derived from a mouse mammary tumor. (1990) (10)
- Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (10)
- Association between gene expression profile of the primary tumor and chemotherapy response of metastatic breast cancer (2017) (9)
- Prognostic immunohistochemical biomarkers of chemotherapy efficacy in biliary tract cancer: A systematic review and meta-analysis. (2019) (9)
- The pathology of familial breast cancer: The pre-BRCA1/BRCA2 era - historical perspectives (1999) (9)
- THE F‐35 JOINT STRIKE FIGHTER AS A SOURCE OF INNOVATIon AND EMPLOYMENT: SOME INTERIM RESULTS (2006) (8)
- A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy. (2019) (8)
- Prediction of response to neoadjuvant chemotherapy in breast cancer. (2006) (6)
- A case-control study to identify molecular risk factors for local recurrence in young breast cancer patients. (2020) (6)
- Low risk of recurrence in elderly patients treated with breast conserving therapy in a single institute. (2016) (6)
- Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (6)
- Legal claims for malignant mesothelioma: dealing with all cases. (2013) (5)
- Recent Advances in Pancreatic Cancer Surgery of Relevance to the Practicing Pathologist. (2016) (5)
- The impact of a pathologist's personality on the interobserver variability and diagnostic accuracy of predictive PD-L1 immunohistochemistry in lung cancer. (2022) (4)
- Prospective validation of craniocaudal tumour size on MR imaging compared to histoPAthology in patients with uterine cervical cancer: The MPAC study (2019) (3)
- Ductal carcinoma in situ of the breast: histological classification and genetic alterations. (1998) (3)
- [Categorization of occult tumour cells in lymph nodes in patients with colon cancer not reliable enough]. (2011) (3)
- Estrogen receptor phenotypes defined by gene expression profiling. (2009) (2)
- Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach (2012) (2)
- Genomic patterns resembling BRCA-mutated breast cancers and benefit of intensified carboplatin-based chemotherapy in HER2-negative breast cancer. (2011) (2)
- Changes in gene expression profiling due to primary chemotherapy in patients with locally advanced breast cancer. (2004) (2)
- Evaluation of early response to preoperative accelerated partial breast irradiation (PAPBI) by histopathology, MRI, and FDG PET/CT. (2021) (2)
- Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer (2022) (2)
- The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021) (1)
- Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences (2019) (1)
- Different effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple-negative invasive ductal breast carcinoma. (2009) (1)
- Functional characterization of the 19q12 amplicon in grade III breast cancers (2012) (1)
- Establishment of the Dutch Nationwide, Interdisciplinary Infrastructure and Biobank for Fundamental and Translational Ovarian Cancer Research: Archipelago of Ovarian Cancer Research (2022) (1)
- Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
- Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer (2019) (1)
- Evaluation of Early Response to Preoperative Accelerated Partial Breast Irradiation (PAPBI) by Histopathology, Magnetic Resonance Imaging, and 18F-fluorodexoyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) (2021) (1)
- Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets (2014) (1)
- Unsupervised class discovery in pancreatic ductal adenocarcinoma reveals cell-intrinsic mesenchymal features and high concordance between existing classification systems (2020) (0)
- Clairvoyance or reliable prediction of the future? (2007) (0)
- Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer (2016) (0)
- Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancer. (2022) (0)
- [Preoperative needle biopsy: an improvement in palpable breast tumors with strong indications for malignancy]. (1996) (0)
- Comprehensive evaluation of methodology to assess abundance of immune infiltrates in breast cancer. (2019) (0)
- Lymphatic mapping of ductal carcinoma in situ diagnosed by stereotactic core needle biopsy. (2006) (0)
- Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
- A specific gene expression signature for visceral organ metastasis in breast cancer (2019) (0)
- Detecting KRAS mutations in pancreatic cystic neoplasms: droplet digital PCR versus targeted next-generation sequencing. (2022) (0)
- Establishment of patient-derived xenograft models and cell lines for malignancies of the upper gastrointestinal tract (2015) (0)
- Association between gene expression profile of the primary tumor and chemotherapy response of metastatic breast cancer (2017) (0)
- Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2). (2001) (0)
- Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer (2022) (0)
- Impact of the Classical and Basal-Like Molecular Subtypes of Pancreatic Cancer on Overall Survival (SPACIOUS-2): A Multicenter Study (2022) (0)
- Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
- [Breast sparing treatment in operable breast carcinoma; initial assessment of the results]. (1983) (0)
- Partially methylated domains are hypervariable in breast cancer and fuel widespread CpG island hypermethylation (2019) (0)
- Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
- GENE EXPRESSION PROFILING OF HIGH STAGE OVARIAN CANCER PATIENTS RELATED TO CLINICAL OUTCOME (2004) (0)
- Translating the Genomic Architecture of Breast Cancer into Clinical Applications (2010) (0)
- HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures (2017) (0)
- Corrigendum to "A case-control study to identify molecular risk factors for local recurrence in young breast cancer patients" [Radiother Oncol 156 (2021) 127-135]. (2021) (0)
- PO-521 Gene expression-based subtypes of pancreatic ductal adenocarcinoma offer leads for targeted therapy (2018) (0)
- Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
- [Breast lesion diagnosis: integrating pathology and radiology]. (2011) (0)
- Abstract P3-09-18: The association between genomic alterations and body mass index in patients with early breast cancer (2022) (0)
This paper list is powered by the following services:
